scm logo

SCM Life Science (SCM Life Science, KOSDAQ 298060, CEO Lee Byung-gun), a company specializing in cell therapy, announced on the 28th that it has completed patent registration for two key source technologies of SCM Biochemistry with the Australian Patent Office. There are two patents on the method of separating and culturing drugs and stem cell layers using controlled T cells. 

The official name of the patent related to regulatory T cell is 'pharmaceutical composition for the prevention or treatment of regulated T cell-mediated diseases'. The patent contains a mechanism of mediating intercellular signal transmission and inducing cell proliferation, and has scalability that can be applied to various inflammatory diseases or autoimmune diseases in the future.

In the field of immuno-oncology, which have recently been in the spotlight in the field of anti-cancer drugs, existing immuno-cancer drugs mainly used "cytotoxic T cell."  In this case, autoimmune effects such as cytokine storms, in which the immune system reacts excessively and harms the body itself, frequently occurred. In the case of anticancer technology using regulated T cells instead of cytotoxic T cells, these side effects can be minimized.

The official name of the patent for Subfractionation Culturing Method is 'Subfractionation Culturing and increase method of stem cells'. Existing stem cell treatments have limitations in that the cost of treatment is high due to the low purity of stem cells and lack of disease-specific treatments.

The original technology, "Subfractionation Culturing Method," is a technology that controls culture cell density low and adds antioxidants to suppress cell stress and improve proliferation capabilities in separating hyperpure stem cells. It has the advantage of being able to produce large amounts of high-quality stem cells in a short time by simplifying the manufacturing process.

In particular, the newly registered Subfractionation Culturing Method is a technology that improves the efficiency of the Subfractionation Culturing Method, which is a source technology that previously holds a global patent. Furthermore, this patent registration is expected to protect the exclusive authority of technology in Australia until 2037.

The improved Subfractionation Culturing Method has been registered in countries such as Korea, Japan, and Russia, and is currently undergoing patent registration screening in major medical countries such as the United States, Europe, and China and around the world, including Indonesia and Malaysia.